LRRK2 and Parkinson disease: The on-going and future ASO and LRRK2 kinase inhibitor targeted approaches will examine if reducing LRRK2 levels and/or kinase activity ameliorates the toxic gain-of-function effects of LRRK2 in PD patients and results in clinically relevant efficacy.